Protocol TMC435HPC2002:An exploratory Phase IIa, randomized, open-label trial to investigate the efficacy and safety of 12 weeks or 24 weeks of TMC435 in combination with PSI-7977 with or without ribavirin in chronic hepatitis C genotype 1-infected prior

Project: Research project

Project Details

Effective start/end date1/26/126/4/14


  • Tibotec Pharmaceuticals Ltd. (Protocol TMC435HPC2002)